Companies · USAspending parent record
RAFA LABORATORIES LTD
No confirmed stock ticker. 1 recipient record grouped under this USAspending parent (UEI CKDNTKNDPMJ6).
obligated to date on 1 non-competed award of $1M+ signed FY2024–26
Obligated to date, not spending in a year. Selected awards only (rule r5-v1): not this company's not-competed share.
obligated to date: 75A50325C00020, Department of Health and Human Services, signed FY2025
No confirmed stock ticker, so no member trades are matched to this company.
Federal contract awards in our records
Each row is one prime contract award on USAspending.gov; “USAspending” opens its official page.
What this table covers: every award signed in FY2024–26 that the agency coded “not competed” and that is $1 million or more, plus any award of $10 million or more (rule r5-v1). Smaller competed awards are not in it, so it is not this company’s total federal business and it cannot show a not-competed share. “Obligated to date” is the total committed on the award so far, including later modifications (USAspending, as of Oct 3, 2026), not the amount at any earlier date.
| Signed in | Non-competed awards | Obligated to date | Other awards $10M+ | Obligated to date |
|---|---|---|---|---|
| FY2024 | None in this set | — | None in this set | — |
| FY2025 | 1 | $33.4M | 1 | $12.0M |
| FY2026incomplete | None in this set | — | None in this set | — |
FY2026 is incomplete: the Department of Defense reports contract actions 90 days late, and older awards keep growing through modifications, so these amounts will rise. Source: USAspending.gov, as of Oct 3, 2026.
| Source | |||||
|---|---|---|---|---|---|
| 75A50325C00020RAFA ATROPINE AUTO-INJECTORS (0.5 MG, 1 MG, AND 2 MG) | Department of Health and Human Services | Sep 30, 2025FY2025 | Not competedOnly one source-other (FAR 6.302-1 other) | $33,392,937 | USAspending |
| 75A50125C00018THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE FOLLOWING DEVELOPMENT ESSENTIALS: CMC DEVELOPMENT, PRE-CLINICAL AND CLINICAL STUDIES, DEVICE DEVELOPMENT ACTIVITIES, HUMAN FACTORS TESTING, MARKET VIABILITY ASSESSMENTS ALONG WITH ALL ASSOCIATED REGULA | Department of Health and Human Services | Sep 30, 2025FY2025 | Full and open competition | $11,997,762 | USAspending |
FY2024–26 awards to RAFA LABORATORIES LTD, largest first (obligated to date)
- 75A50325C00020RAFA ATROPINE AUTO-INJECTORS (0.5 MG, 1 MG, AND 2 MG)
- Signed
- Sep 30, 2025FY2025
- Competition
- Not competedOnly one source-other (FAR 6.302-1 other)
- Obligated to date
- $33,392,937
- 75A50125C00018THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE FOLLOWING DEVELOPMENT ESSENTIALS: CMC DEVELOPMENT, PRE-CLINICAL AND CLINICAL STUDIES, DEVICE DEVELOPMENT ACTIVITIES, HUMAN FACTORS TESTING, MARKET VIABILITY ASSESSMENTS ALONG WITH ALL ASSOCIATED REGULA
- Signed
- Sep 30, 2025FY2025
- Competition
- Full and open competition
- Obligated to date
- $11,997,762
Recipient records grouped under this company (1)
USAspending groups recipients by its parent-company field, which has known errors. Check that the recipients below belong to RAFA LABORATORIES LTD; the stock link below is made per recipient.
- RAFA LABORATORIES LTD2 awards · 1 non-competed, $33.4M obligated to date
Stock ticker
Links between a federal contract recipient and an SEC-registered company, made by a written rule from SEC filings and USAspending records. Only confirmed links are shown.
No confirmed stock ticker: this may be a private company, a subsidiary awaiting review, or not matched to an SEC registrant.
Members of Congress who reported trading this stock
No confirmed stock ticker: this may be a private company, a subsidiary awaiting review, or not matched to an SEC registrant. Without a confirmed ticker, no trades are matched to this company.
Looking for agency-level shares? See non-competed share by agency.